AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009

Backup compound to AstraZeneca’s failed Exanta is being investigated for a stability limitation; Crestor is the only branded statin to increase U.S. market share during 2008.